Edition:
India

Cytokinetics Inc (CYTK.OQ)

CYTK.OQ on NASDAQ Stock Exchange Global Select Market

7.20USD
23 Apr 2018
Change (% chg)

-- (--)
Prev Close
$7.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
121,426
52-wk High
$17.20
52-wk Low
$6.80

Select another date:

Fri, Feb 16 2018

BRIEF-Cytokinetics Qtrly Net Loss Per Share $0.75

* CYTOKINETICS, INC. REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS

Continue Reading

BRIEF-Cytokinetics Announces Progress Against Vision 2020

* CYTOKINETICS INC - ‍RESULTS FROM FOUR CLINICAL TRIALS OF CK-2127107 EXPECTED IN 2018​

Cytokinetics sinks on abandoning ALS drug after failed trial

Cytokinetics Inc shares plummeted nearly 28 percent on Tuesday after the drugmaker said it would stop developing one of its treatments for ALS, a fatal neuro-degenerative disorder, after the drug failed to improve lung function in a key trial.

BRIEF-Cytokinetics Inc announces negative results from VITALITY-ALS

* Phase 3 clinical trial of Tirasemtiv in patients with ALS did not meet primary or secondary endpoints​

Cytokinetics' neuro-degenerative drug fails late-stage trial

Nov 21 Cytokinetics Inc said on Tuesday its drug to treat a type of neuro-degenerative disorder failed to meet the main goal of a late-stage trial.

BRIEF-Cytokinetics files for potential mixed shelf, size undisclosed‍​

* Cytokinetics Inc files for potential mixed shelf, size undisclosed - SEC Filing ‍​ Source text: http://bit.ly/2hauCBo Further company coverage:

BRIEF-Cytokinetics enters into second amendment to certain loan and security agreement

* Cytokinetics - ‍on Oct 27, entered into second amendment to certain loan and security agreement dated as of October 19, 2015

BRIEF-Cytokinetics reports Q3 loss of ‍$0.60/shr​

* Cytokinetics, Inc. reports third quarter 2017 financial results

Select another date:

Market Views

» More CYTK.OQ Market Views